A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

NCT06042920 PHASE4 TERMINATED Results posted

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE4
Status	TERMINATED
Enrolment	130
Start date	Mon Oct 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Apr 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Palmoplantar Psoriasis
• Genital Psoriasis

Interventions

• Deucravacitinib
• Placebo

Countries

Argentina, Canada, United States